SCHEMBL282476

SCHEMBL282476

COC(=O)c1cc(Cl)c(Oc2ccc(OC)c(C(C)C)c2)c(Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
RORC P51449 12/20 0.66
THRB P10828 8/20 0.66
THRA P10827 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5619231 0.89 THRB (0.73) RORCTHRBTHRA
SCHEMBL7054420 0.88 RORC (0.53) RORCTHRBTHRA
SCHEMBL6368421 0.88 RORC (0.64) RORCTHRBTHRA
SCHEMBL282114 0.86 THRB (0.51) RORCTHRBTHRA
SCHEMBL7054452 0.85 THRB (0.57) RORCTHRBTHRA
SCHEMBL283245 0.84 THRB (0.61) RORCTHRBTHRA
SCHEMBL5284091 0.83 RORC (0.60) RORCTHRBTHRA
SCHEMBL22959162 0.83 RORC (0.70) RORCTHRBTHRA
SCHEMBL22959176 0.83 RORC (0.70) RORCTHRBTHRA
SCHEMBL7073261 0.81 RORC (0.65) RORCTHRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689383-B1 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS INC (US) 2012-10-31 EP disclosed
EP-2428516-A1 Novel phosphorus-containing thyromimetics Metabasis Therapeutics, Inc. (US) 2012-03-14 EP disclosed
US-7829552-B2 Phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. (US) 2010-11-09 US disclosed
US-20100081634-A1 Novel Phosphorus-Containing Thyromimetics METABASIS THERAPEUTICS, INC. (US) 2010-04-01 US disclosed
US-20090118236-A1 Novel Phosphorus-Containing Thyromimetics CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2009-05-07 US disclosed
US-7514419-B2 Phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. (US) 2009-04-07 US disclosed
US-20090028925-A1 Novel Phosphinic Acid-Containing Thyromimetics METABASIS THERAPEUTICS, INC. 2009-01-29 US disclosed
EP-1890768-A2 NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS Metabasis Therapeutics, Inc. (US) 2008-02-27 EP disclosed
WO-2006128056-A2 NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 WO disclosed
US-20060046980-A1 Novel phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. 2006-03-02 US disclosed
EP-1000008-B1 NOVEL THYROID RECEPTOR LIGANDS AND METHOD KAROBIO AB (SE) 2003-06-25 EP disclosed
US-6465687-B1 SUBSTITUTED 4-HYDROXY-3-ALKYL- OR CYCLOALKYL-PHENOXYBENZENE COMPOUNDS SUCH AS 3,5-DIBROMO-4-(4-HYDROXY-3-ISOPROPYLPHENOXY)BENZOIC ACID, EXPRESSION INHIBITION OF A T3 REGULATED GENE KARO BIO AB (SE) 2002-10-15 US disclosed
EP-1185229-A1 METHOD OF TREATING HAIR LOSS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2002-03-13 EP disclosed
WO-2000072811-A1 METHOD OF TREATING HAIR LOSS THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081634-A1 Novel Phosphorus-Containing Thyromimetics PYGL, THRA, THOP1 RORC 648/4885THRB 6/4885THRA 2/4885
US-20060046980-A1 Novel phosphorus-containing thyromimetics PYGL, THRA, THOP1 RORC 648/4885THRB 6/4885THRA 2/4885
US-20090118236-A1 Novel Phosphorus-Containing Thyromimetics THRA, PYGL, THRB RORC 656/4885THRB 3/4885THRA 1/4885
US-20090028925-A1 Novel Phosphinic Acid-Containing Thyromimetics PYGL, PHOSPHO1, LIPE RORC 781/4885THRB 41/4885THRA 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.